233 related articles for article (PubMed ID: 25635861)
21. Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency.
Louie SG; Sclar DA; Gill MA
Ann Pharmacother; 2005 Nov; 39(11):1861-9. PubMed ID: 16219903
[TBL] [Abstract][Full Text] [Related]
22. Biochemical comparison of four commercially available human α
Boerema DJ; An B; Gandhi RP; Papineau R; Regnier E; Wilder A; Molitor A; Tang AP; Kee SM
Biologicals; 2017 Nov; 50():63-72. PubMed ID: 28882403
[TBL] [Abstract][Full Text] [Related]
23. Acute-phase protein α1-antitrypsin--a novel regulator of angiopoietin-like protein 4 transcription and secretion.
Frenzel E; Wrenger S; Immenschuh S; Koczulla R; Mahadeva R; Deeg HJ; Dinarello CA; Welte T; Marcondes AM; Janciauskiene S
J Immunol; 2014 Jun; 192(11):5354-62. PubMed ID: 24760148
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the association of MPO and MMP-9 with stroke severity and outcome: Cohort study.
Maestrini I; Tagzirt M; Gautier S; Dupont A; Mendyk AM; Susen S; Tailleux A; Vallez E; Staels B; Cordonnier C; Leys D; Bordet R
Neurology; 2020 Jul; 95(1):e97-e108. PubMed ID: 32111692
[TBL] [Abstract][Full Text] [Related]
25. Alpha 1-antitrypsin augmentation therapy.
Sandhaus RA
Agents Actions Suppl; 1993; 42():97-102. PubMed ID: 8356934
[TBL] [Abstract][Full Text] [Related]
26. Commercial plasma alpha1-antitrypsin (Prolastin) contains a conformationally inactive, latent component.
Lomas DA; Elliott PR; Carrell RW
Eur Respir J; 1997 Mar; 10(3):672-5. PubMed ID: 9073003
[TBL] [Abstract][Full Text] [Related]
27. [Augmentation therapy with alpha-1 antitrypsin: 20 year- follow-up of a deficient patient].
Pujazon MC; Carles P
Rev Mal Respir; 2008 Nov; 25(9):1136-41. PubMed ID: 19106912
[TBL] [Abstract][Full Text] [Related]
28. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase.
Ogushi F; Fells GA; Hubbard RC; Straus SD; Crystal RG
J Clin Invest; 1987 Nov; 80(5):1366-74. PubMed ID: 3500183
[TBL] [Abstract][Full Text] [Related]
29. Alpha-1 antitrypsin augmentation therapy.
Wewers MD; Crystal RG
COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
[TBL] [Abstract][Full Text] [Related]
30. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
31. Alpha-1 Antitrypsin-Deficient Macrophages Have Increased Matriptase-Mediated Proteolytic Activity.
Krotova K; Marek GW; Wang RL; Aslanidi G; Hoffman BE; Khodayari N; Rouhani FN; Brantly ML
Am J Respir Cell Mol Biol; 2017 Aug; 57(2):238-247. PubMed ID: 28362108
[TBL] [Abstract][Full Text] [Related]
32. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.
Dirksen A; Piitulainen E; Parr DG; Deng C; Wencker M; Shaker SB; Stockley RA
Eur Respir J; 2009 Jun; 33(6):1345-53. PubMed ID: 19196813
[TBL] [Abstract][Full Text] [Related]
33. Comparative biochemical efficacy analysis of an alpha
Li Z; Franke RM; Morris D; Yel L
Pulm Pharmacol Ther; 2022 Jun; 73-74():102124. PubMed ID: 35314325
[TBL] [Abstract][Full Text] [Related]
34. [Analysis of alpha-1-antitrypsin phenotypes and genotypes in patients with early-onset pulmonary emphysema].
Dwomiczak S; Ziora D; Konofalski L; Szalaty M; Kowalska A; Kozielski J
Pneumonol Alergol Pol; 2005; 73(1):12-7. PubMed ID: 16539178
[TBL] [Abstract][Full Text] [Related]
35. Propionate induces the release of granules from bovine neutrophils.
Carretta MD; Conejeros I; Hidalgo MA; Burgos RA
J Dairy Sci; 2013 Apr; 96(4):2507-2520. PubMed ID: 23403200
[TBL] [Abstract][Full Text] [Related]
36. Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK).
Campos MA; Kueppers F; Stocks JM; Strange C; Chen J; Griffin R; Wang-Smith L; Brantly ML
COPD; 2013 Dec; 10(6):687-95. PubMed ID: 23862647
[TBL] [Abstract][Full Text] [Related]
37. Impact of HIV infection on α
Stephenson SE; Wilson CL; Crothers K; Attia EF; Wongtrakool C; Petrache I; Schnapp LM
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L583-L592. PubMed ID: 29351445
[TBL] [Abstract][Full Text] [Related]
38. Augmentation therapy of alpha-1 antitrypsin deficiency associated emphysema.
Traclet J; Delaval P; Terrioux P; Mornex JF
Rev Mal Respir; 2015 Apr; 32(4):435-46. PubMed ID: 25908241
[TBL] [Abstract][Full Text] [Related]
39. Different forms of alpha-1 antitrypsin and neutrophil activation mediated by human anti-PR3 IgG antibodies.
Surmiak M; Sanak M
Pharmacol Rep; 2016 Dec; 68(6):1276-1284. PubMed ID: 27689755
[TBL] [Abstract][Full Text] [Related]
40. Severe panniculitis caused by homozygous ZZ alpha1-antitrypsin deficiency treated successfully with human purified enzyme (Prolastin).
Chowdhury MM; Williams EJ; Morris JS; Ferguson BJ; McGregor AD; Hedges AR; Stamatakis JD; Pope FM
Br J Dermatol; 2002 Dec; 147(6):1258-61. PubMed ID: 12452881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
